ISPOR 20th Annual European Congress
Glasgow, Scotland
November, 2017
PRS25
Respiratory Disorders (including Chronic Obstructive Pulmonary Disease [COPD]
Cost Studies (CS)
Cost of Illness (CoI)
EVIDENCE MAP OF COSTS STUDIES IN CYSTIC FIBROSIS SINCE 2000
Martin A
Crystallise Ltd., East Tilbury, UK
OBJECTIVES:  To create an evidence map of studies reporting the direct and indirect costs associated with cystic fibrosis, and the geographical settings in which these studies were conducted. METHODS:  We searched the heoro.com database (www.heoro.com) for costs studies in cystic fibrosis published between 2000 and 17 May 2017. We analysed the abstracts identified by the search to determine the different types of costs reported across the range of geographical locations and interventions. We presented the findings as an evidence map. RESULTS:  We found a total of 60 abstracts. Of these, 58 reported direct costs from 11 countries and seven reported indirect costs from five countries. The most common setting was the United States, with 15 abstracts, followed by the UK (13), Australia (7), Canada (6), Germany and France (3 each), the Netherlands (2) and Brazil, Denmark and New Zealand (1 each). Nine studies were reviews of the international literature. Fourteen studies reported costs of healthcare in general. Specific interventions studied included prenatal or neonatal screening (18 abstracts), antibiotics for respiratory infections (usually Pseudomonas, 11 abstracts), rhDNase and lung transplants and associated treatments (4 abstracts each). Twenty five abstracts were economic models and 24 were cost studies. CONCLUSIONS:  As with many diseases, there is a relative lack of published data on indirect costs of cystic fibrosis, and two-thirds of studies reporting cost data were from just four jurisdictions: Australia, Canada, the UK and the USA.